Encorafenib ( LGX818; LGX-818; LGX 818; Encorafenib )

Catalog No. M17919 CAS No. 1269440-17-6

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Group Booking Get Quotation Bulk Inquiry Add to Cart

Product Name

Encorafenib
Note

Research use only, not for human use.
Brief Description

LGX818 is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.
Description

Encorafenib, also known as LGX-818, is an orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells.
Synonyms

LGX818; LGX-818; LGX 818; Encorafenib
Pathway

Cell Cycle/DNA Damage
Target

HDAC
Recptor

B-Raf (V600E)
Research Area

Cancer
Indication

——

CAS Number

1269440-17-6
Formula Weight

540.01
Molecular Formula

C22H27ClFN7O4S
Purity

98%
Solubility

DMSO : 50 mg/mL 92.59 mM;
SMILES

C[C@@H](CNC1=NC=CC(=N1)C2=CN(N=C2C3=CC(=CC(=C3F)NS(=O)(=O)C)Cl)C(C)C)NC(=O)OC
Chemical Name

(S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate.

1. Darrin D Stuart, et al. Cancer Res, 2012, 72(8 Supplement): 3790.

Calculator

molnova catalog